Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

The Addition of Romidepsin to CHOEP and High-Dose Chemotherapy Plus Stem Cell Transplantation Did Not Ameliorate the Outcome of Untreated Angioimmunoblastic T-Cell or Follicular T-Helper Lymphoma: Subgroup Analysis of Phase II FIL-PTCL13 Study

Blood (2022) 140 (Supplement 1): 6538–6539.

https://doi.org/10.1182/blood-2022-163824

Published: 2022

Journal Articles

Total Metabolic Tumor Volume Is Confirmed As Independent Prognostic Factor in Treatment Naïve Follicular Lymphoma Patients and Can be Combined with FLIPI2 to Improve Prognostic Accuracy. a FOLL12 Substudy By the Fondazione Italiana Linfomi

Blood (2022) 140 (Supplement 1): 1313–1315.

https://doi.org/10.1182/blood-2022-166225

Published: 2022

Journal Articles

Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphoma

Blood (2022) 140 (12): 1378–1389.

https://doi.org/10.1182/blood.2021014270

Published: 2022

Includes: Supplemental data

Journal Articles

Adding Romidepsin to CHOEP in First Line Treatment of Peripheral T-Cell Lymphomas Does Not Improve the Response Rate: Final Analysis of Phase II PTCL13 Study

Blood (2021) 138 (Supplement 1): 134.

https://doi.org/10.1182/blood-2021-153680

Published: 2021

Journal Articles

Rituximab Plus Bendamustine and Cytarabine (R-BAC) in Elderly Patients with Newly Diagnosed Mantle Cell Lymphoma: Long Term Follow-up and Mrd Results of a Phase 2 Study from the Fondazione Italiana Linfomi

Blood (2021) 138 (Supplement 1): 384.

https://doi.org/10.1182/blood-2021-153364

Published: 2021

Journal Articles

The Prognostic Relevance of Comprehensive Risk Score Is Modulated By Therapy: Analysis of 292 Acute Myeloid Leukemia Patients Registered at the Genova Acute Leukemia Registry (REGAL)

Fabio Guolo, MD, Paola Minetto, MD, Elena Clavio, Giordana Pastori, MD, Daniela Guardo, MD, Lisette Del Corso, MD, Chiara Ghiggi, PhD, Maurizio Miglino, PhD, Germana Beltrami, MD, Angelo Michele Carella, Roberto Massimo Lemoli, MD, Andrea Bacigalupo, MD, Marco Gobbi, MD, Marino Clavio, MD

Blood (2015) 126 (23): 4885.

https://doi.org/10.1182/blood.V126.23.4885.4885

Published: 2015

Journal Articles

High Predictive Value of Pre Transplant Minimal Residual Disease Assessment By Combining WT1 Expression and Flow Cytometry in Acute Myeloid Leukemia

Fabio Guolo, MD, Federica Galaverna, MD, Paola Minetto, MD, Livia Giannoni, MD, Chiara Ghiggi, PhD, Marino Clavio, MD, Carmen Di Grazia, MD, Anna Maria Raiola, MD, Nicoletta Colombo, PhD, Raffaella Grasso, PhD, Maurizio Miglino, PhD, Adalberto Ibatici, MD, Roberto Massimo Lemoli, MD, Marco Gobbi, MD, Andrea Bacigalupo, MD

Blood (2015) 126 (23): 2029.

https://doi.org/10.1182/blood.V126.23.2029.2029

Published: 2015

Journal Articles

Prognostic Value of Minimal Residual Disease Assessed By WT1 Expression Level and Flow Cytometry in Acute Myeloid Leukemia Patients Undergoing Allogeneic Marrow Transplantation

Livia Giannoni, MD, Fabio Guolo, MD, Paola Minetto, MD, Federica Galaverna, MD, Chiara Ghiggi, MD, Marino Clavio, MD, Samuele Bagnasco, MD, Carmen Di Grazia, MD, Raffaella Grasso, PhD, Nicoletta Colombo, PhD, Daniele Avenoso, MD, Giordana Pastori, MD, Filippo Ballerini, MD, Annalisa Kunkl, PhD, Maurizio Miglino, PhD, Roberto Lemoli, MD, Marco Gobbi, MD, Andrea Bacigalupo, MD

Blood (2014) 124 (21): 1027.

https://doi.org/10.1182/blood.V124.21.1027.1027

Published: 2014

Journal Articles

Interferon-Alpha (IFN-a) Is Able To Maintain Complete Molecular Response (CMR) In Chronic Myeloid Leukemia (CML) Patients Who Maintain Undetectable disease After Imatinib (IM) Discontinuation

Angelo Michele Carella, MD, Germana Beltrami, MD, Chiara Ghiggi, MD

Blood (2013) 122 (21): 5195.

https://doi.org/10.1182/blood.V122.21.5195.5195

Published: 2013

Journal Articles

Detection of an Unbalanced Ratio Between WT1 Isoforms in Acute Myeloid Leukemia and Its Correlation with Molecular Abnormalities.

Chiara Calabrese, PhD, Gian Matteo Pica, MD, Enrico Bracco, PhD, Anna Serra, PhD, Francesca Carnuccio, PhD, Sonia Carturan, PhD, Valentina Campia, PhD, Chiara Ghiggi, PhD, Fabio Guolo, PhD, Angelo Michele Carella, MD, Nicoletta Colombo, PhD, Raffaella Grasso, PhD, Maurizio Miglino, PhD, Francesco Frassoni, Giuseppe Saglio, MD, Daniela Cilloni, MD

Blood (2012) 120 (21): 2500.

https://doi.org/10.1182/blood.V120.21.2500.2500

Published: 2012

Journal Articles

2′–Cyano–2′–Deoxyarabinofuranosylcytosine Is Active in Acute Myeloid Leukaemia and Acts in Synergy with Cytarabine.

Elisabeth J Walsby, Chiara Ghiggi, Ruth H Mackay, Simon R Green, Steven Knapper, Alan K Burnett

Blood (2009) 114 (22): 4153.

https://doi.org/10.1182/blood.V114.22.4153.4153

Published: 2009

NARROW

The Addition of Romidepsin to CHOEP and High-Dose Chemotherapy Plus Stem Cell Transplantation Did Not Ameliorate the Outcome of Untreated Angioimmunoblastic T-Cell or Follicular T-Helper Lymphoma: Subgroup Analysis of Phase II FIL-PTCL13 Study

Total Metabolic Tumor Volume Is Confirmed As Independent Prognostic Factor in Treatment Naïve Follicular Lymphoma Patients and Can be Combined with FLIPI2 to Improve Prognostic Accuracy. a FOLL12 Substudy By the Fondazione Italiana Linfomi

Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphoma

Adding Romidepsin to CHOEP in First Line Treatment of Peripheral T-Cell Lymphomas Does Not Improve the Response Rate: Final Analysis of Phase II PTCL13 Study

Rituximab Plus Bendamustine and Cytarabine (R-BAC) in Elderly Patients with Newly Diagnosed Mantle Cell Lymphoma: Long Term Follow-up and Mrd Results of a Phase 2 Study from the Fondazione Italiana Linfomi

The Prognostic Relevance of Comprehensive Risk Score Is Modulated By Therapy: Analysis of 292 Acute Myeloid Leukemia Patients Registered at the Genova Acute Leukemia Registry (REGAL)

High Predictive Value of Pre Transplant Minimal Residual Disease Assessment By Combining WT1 Expression and Flow Cytometry in Acute Myeloid Leukemia

Prognostic Value of Minimal Residual Disease Assessed By WT1 Expression Level and Flow Cytometry in Acute Myeloid Leukemia Patients Undergoing Allogeneic Marrow Transplantation

Interferon-Alpha (IFN-a) Is Able To Maintain Complete Molecular Response (CMR) In Chronic Myeloid Leukemia (CML) Patients Who Maintain Undetectable disease After Imatinib (IM) Discontinuation

Detection of an Unbalanced Ratio Between WT1 Isoforms in Acute Myeloid Leukemia and Its Correlation with Molecular Abnormalities.

2′–Cyano–2′–Deoxyarabinofuranosylcytosine Is Active in Acute Myeloid Leukaemia and Acts in Synergy with Cytarabine.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only